The CBD maker said state-level changes in hemp laws as public health concerns rise are impeding attempts to expand its retail ...

The struggling psychedelics firm abandoned direct patient care in favor of developing tech for insurance reimbursement and ...

The delay is at least the second such move by the USDA, the agency said in a press release, after it made a similar decision ...

The firm's tried to shore up its position as the FDA and Health Canada cleared Phase II trials for its flagship psilocybin ...

Ditching cannabis growing tech for hemp-based drinks marks a new era for the firm under its new GTI leadership.

The Toronto-based drugmaker's revenue held steady, helped by stronger performance from its Colombian operations.

The biotech reported progress on its lead molecule and out-licensed two candidates, amid cash constraints and a potential ...

Unpack the industry with the daily cannabis newsletter for business leaders.

While broader real estate stocks rallied on the Federal Reserve’s latest rate cut, with the Real Estate Select Sector SPDR ...

The company did not specify in Tuesday's announcement whether previously announced layoffs and closures would be reversed.

Regulators outlined recommendations and rules related to creating a safe working environment for those working with cannabis.

A new credit facility provided $8 million in net proceeds for growth initiatives ahead of a planned mid-2025 integration with ...